Entera Bio Ltd. ENTX 深 沪
已收盘 09-19 16:00:00 美东时间
1.80
0.000
0.00%
华盛通- 最 高1.82
- 今 开1.81
- 成交量 4.62万股
- 最 低 1.78
- 昨 收 1.80
- 总市值 8219.41万
- 52周最高 2.79
- 市盈率 静 --
- 换手率 0.10%
- 52周最低 1.5006
- 委 比 -41.34%
- 总股本 4566.34万
- 历史最高 10.16
- 量 比 0.63
- 振 幅 2.22%
- 历史最低 0.472
- 每 手 1
- 风险率 0.22%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Entera Bio Presents Preclinical Data For OPK-8801003, Oral GLP-2 Tablet With Longer Half-Life Aiming To Replace Daily Injections For Short Bowel Syndrome Patients
Preclinical Data for OPK-8801003 Demonstrate Substantially Longer Biological Half-Life with Peak Plasma Levels Comparable to Gattex®, the Only Approved GLP-2 TherapyOral GLP-2 Tablet Could Transform Treatment
09-15 21:05
Entera Bio To Present EB613 Phase 2 Data At ASBMR 2025; Oral Anabolic Tablet Advances Toward Phase 3
EB613 Demonstrates Significant Effects on Both Trabecular and Cortical Bone Compartments After Just 6 Months of Treatment in Phase 2 Study; Cortical Improvements Comparable to Injectable Teriparatide and
09-08 20:33
Entrada Therapeutics Announces Recipients of Third Annual DREAMS Grant Program
Entrada Therapeutics announced the recipients of its 2025 DREAMS Grant Program, awarding $50,000 each to Jett Foundation (U.S.) and Parent Project aps (Italy). These grants support programs advancing equity, accessibility, and inclusion for individuals with Duchenne muscular dystrophy in the U.S., EU, and U.K. Jett Foundation's Camp Promise provides year-round support for underserved individuals aged 18 and older, while Parent Project aps deliver...
09-05 11:00
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Entrada Therapeutics granted 54,360 RSUs and options to purchase 38,850 shares to seven newly-hired employees under its 2025 Inducement Equity Plan. Options have an exercise price of $5.47 per share, vesting 25% after the first year, with the remaining 75% vesting monthly over three years. RSUs vest 25% after the first year, followed by 6.25% quarterly. The grants aim to incentivize new employees, as approved by the Compensation Committee.
09-02 20:30
Entera Bio to Unveil Clinical and Non-Clinical Data Across 3 Oral Peptide Programs at Upcoming September Conferences
Entera Bio Ltd. will present data on three key programs in September 2025. At the ASBMR Annual Meeting, they will discuss EB613, an oral PTH(1-34) tablet for postmenopausal osteoporosis, and next-gen EB613. At ESPEN, they will present on an oral GLP-2 analog for short bowel syndrome. CEO Miranda Toledano will also provide a corporate overview at the H.C. Wainwright Investor Conference.
08-28 12:00
Entera Bio Q2 EPS $(0.06) Misses $1.21 Estimate
Entera Bio (NASDAQ:ENTX) reported quarterly losses of $(0.06) per share which missed the analyst consensus estimate of $1.21 by 104.96 percent. This is unchanged from the same period last year.
08-09 04:10
Entrada Therapeutics Reports Second Quarter 2025 Financial Results
Entrada Therapeutics reported Q2 2025 financial results and highlighted key milestones, including the first patient dosed in the ELEVATE-44-201 study and initiation of ELEVATE-45-201. Multiple clinical trial sites in the U.K. and EU are activated. The company expanded its leadership team with Navid Khan, PhD, and Kiran Patki, MD, to support its growing pipeline. Cash reserves of $354 million are expected to fund operations into Q2 2027. Data from...
08-06 11:00
Entera Bio Advances EB613 with FDA Approval
The latest update is out from Entera Bio ( ($ENTX) ). On July 28, 2025, Entera ...
07-28 19:59
Entera Bio Receives FDA Agreement To Support EB613 NDA Filing With Single 24-Month Global Phase 3 Study In Postmenopausal Osteoporosis, Using Total Hip BMD As Primary Endpoint And Vertebral Fracture Incidence As Key Secondary
Entera Bio Ltd. (NASDAQ:ENTX), a leader in the development of oral peptides and protein replacement therapies, announced today that in a written response to a Type A meeting request, the U.S. Food and Drug Administration
07-28 19:32
Entera Bio Receives FDA Agreement on BMD as Primary Endpoint for EB613 Registrational, Phase 3 Study in Post-Menopausal Women with Osteoporosis
Entera Bio announced that the FDA has agreed to support the NDA filing for EB613, an oral osteoanabolic treatment for postmenopausal osteoporosis, with a single Phase 3 study. The study will use change in total hip BMD as the primary endpoint, marking a shift from traditional fracture-based primary endpoints. The company highlights EB613 as the first oral, daily anabolic tablet aiming to address the unmet need for an alternative to injectable tre...
07-28 11:30
